Aberdeen Group plc Acquires 286,206 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Aberdeen Group plc increased its stake in Teva Pharmaceutical Industries by 56.7%, acquiring an additional 286,206 shares and increasing its total holdings to 790,598 shares valued at approximately $12.15 million.
• Debt-to-equity ratio for Teva Pharmaceutical Industries stands at 2.45, affecting its financial stability, while the company reported a net margin of -0.95% for the last quarter.
• Teva has received multiple upgrades from analysts, with an average target price set at $24.71, reflecting a largely positive outlook for the company's stock.

Aberdeen Group plc boosted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 56.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 790,598 shares of the company's stock after purchasing an additional 286,206 shares during the period. Aberdeen Group plc owned approximately 0.07% of Teva Pharmaceutical Industries worth $12,151,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. lifted its stake in Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company's stock worth $38,487,000 after purchasing an additional 134,705 shares during the last quarter. Financial Sense Advisors Inc. lifted its stake in Teva Pharmaceutical Industries by 63.5% in the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock worth $6,231,000 after purchasing an additional 157,421 shares during the last quarter. King Wealth Management Group increased its position in shares of Teva Pharmaceutical Industries by 1,106.9% in the first quarter. King Wealth Management Group now owns 175,000 shares of the company's stock valued at $2,690,000 after acquiring an additional 160,500 shares during the period. GAMMA Investing LLC increased its position in shares of Teva Pharmaceutical Industries by 804.7% in the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company's stock valued at $1,037,000 after acquiring an additional 60,016 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Teva Pharmaceutical Industries by 1.2% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock valued at $404,775,000 after acquiring an additional 300,000 shares during the period. 54.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on TEVA. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $18.08 on Tuesday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The company's 50-day moving average is $16.69 and its 200 day moving average is $16.24. The stock has a market capitalization of $20.74 billion, a P/E ratio of -113.00, a P/E/G ratio of 1.06 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. During the same quarter in the previous year, the company earned $0.61 earnings per share. Teva Pharmaceutical Industries's quarterly revenue was up .3% on a year-over-year basis. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,001 shares of company stock worth $996,958. 0.49% of the stock is currently owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.